Xiaoping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoping Li has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Jinghua Yuan
12 shared publicationsXinling Zhang
10 shared publications- Xinling Zhang
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China
8 shared publications Yue Xu
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, P. R. China
8 shared publicationsKeyi Chen
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, China
7 shared publicationsShiyu Chen
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, China
7 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 10 (5) , 026260304
Targeted therapy resistance in EGFR-mutant non-small cell lung cancer: Roles of MET, Trop-2-directed antibody–drug conjugates, and molecular monitoring
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major barrier to durable disease control. Objective: This narrative review summarizes the major mechanisms of EGFR-TKI resistance and evaluates the roles of mesenchymal–epithelial transition factor (MET)-targeted therapy, trophoblast cell-surface antigen 2 (Trop-2)-directed antibody–drug conjugates (ADCs), and molecular monitoring in post-resistance management. Methods: Relevant randomized controlled trials, translational studies, and consensus guidelines on targeted therapy resistance in NSCLC were identified from PubMed and Web of Science, with emphasis on recent high-quality evidence and seminal studies. Results: EGFR-TKI resistance arises through on-target EGFR alterations, bypass pathway activation, histologic transformation, and non-genetic adaptation. MET amplification is a clinically relevant bypass mechanism, particularly after third-generation EGFR-TKI exposure, and may support combined EGFR/MET inhibition when confirmed using assay-specific criteria. Trop-2-directed ADCs provide a non-genotype-dependent treatment option for patients with heterogeneous or non-actionable resistance, although Trop-2 expression is not yet a validated universal predictive biomarker. Plasma circulating tumor DNA can facilitate rapid detection of emerging resistance, but negative or discordant plasma findings should be interpreted together with tissue biopsy, disease distribution, and the possibility of histologic transformation. Minimal residual disease assessment remains investigational for treatment-guided decision-making. Conclusion: Post-EGFR-TKI management should follow a mechanism-guided framework integrating progression pattern, tissue and plasma reassessment, biomarker-specific interpretation, matched therapy, and longitudinal molecular monitoring. Prospective studies are needed to standardize testing thresholds and optimize treatment sequencing.
- 23 September 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 10 (5) , 026260304
Open AccessTargeted therapy resistance in EGFR-mutant non-small cell lung cancer: Roles of MET, Trop-2-directed antibody–drug conjugates, and molecular monitoring
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major barrier to durable disease control. Objective: This narrative review summarizes the major mechanisms of EGFR-TKI resistance and evaluates the roles of mesenchymal–epithelial transition factor (MET)-targeted therapy, trophoblast cell-surface antigen 2 (Trop-2)-directed antibody–drug conjugates (ADCs), and molecular monitoring in post-resistance management. Methods: Relevant randomized controlled trials, translational studies, and consensus guidelines on targeted therapy resistance in NSCLC were identified from PubMed and Web of Science, with emphasis on recent high-quality evidence and seminal studies. Results: EGFR-TKI resistance arises through on-target EGFR alterations, bypass pathway activation, histologic transformation, and non-genetic adaptation. MET amplification is a clinically relevant bypass mechanism, particularly after third-generation EGFR-TKI exposure, and may support combined EGFR/MET inhibition when confirmed using assay-specific criteria. Trop-2-directed ADCs provide a non-genotype-dependent treatment option for patients with heterogeneous or non-actionable resistance, although Trop-2 expression is not yet a validated universal predictive biomarker. Plasma circulating tumor DNA can facilitate rapid detection of emerging resistance, but negative or discordant plasma findings should be interpreted together with tissue biopsy, disease distribution, and the possibility of histologic transformation. Minimal residual disease assessment remains investigational for treatment-guided decision-making. Conclusion: Post-EGFR-TKI management should follow a mechanism-guided framework integrating progression pattern, tissue and plasma reassessment, biomarker-specific interpretation, matched therapy, and longitudinal molecular monitoring. Prospective studies are needed to standardize testing thresholds and optimize treatment sequencing.
- Open Access
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 19, 1909580
Epigenetic regulation in medulloblastoma: from tumor heterogeneity to diagnostic, prognostic, and translational applications
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Epigenetic dysregulation, particularly in Group 3 and Group 4 tumors, is a major driver of tumorigenesis despite relatively few recurrent driver mutations. DNA methylation, histone modification, chromatin remodeling, and non-coding RNAs orchestrate aberrant transcriptional programs governing tumor initiation, progression, and cellular identity. Single-cell and multi-omic studies have revealed epigenetic heterogeneity, cellular plasticity, and microenvironmental interactions underlying therapeutic resistance. Epigenetic alterations provide valuable diagnostic and prognostic biomarkers. DNA methylation profiling is the gold standard for molecular classification, while epigenetic signatures and cerebrospinal fluid circulating tumor DNA support precision diagnosis and disease monitoring. This review integrates recent advances in MB epigenetics into a framework linking cellular plasticity and the tumor microenvironment to biomarker-driven precision therapies. Several comprehensive reviews have summarized the epigenetic landscape of medulloblastoma, focusing primarily on DNA methylation, histone modifications, chromatin remodeling, and subgroup-specific epigenetic alterations. While these studies have substantially advanced our understanding of epigenetic mechanisms, the rapid emergence of single-cell sequencing, spatial transcriptomics, multi-omic integration, and three-dimensional chromatin mapping has reshaped the current view of medulloblastoma biology. These technologies provide unprecedented resolution for dissecting intratumoral heterogeneity, developmental trajectories, and dynamic epigenetic regulation not fully addressed in earlier reviews. In this review, we integrate these recent advances into a unified framework connecting classical epigenetic mechanisms with emerging multidimensional epigenomic technologies. We discuss how these insights facilitate biomarker discovery, improve molecular classification, and accelerate precision epigenetic therapies, highlighting future directions for translational research.
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 19, 1909580
Open AccessEpigenetic regulation in medulloblastoma: from tumor heterogeneity to diagnostic, prognostic, and translational applications
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Epigenetic dysregulation, particularly in Group 3 and Group 4 tumors, is a major driver of tumorigenesis despite relatively few recurrent driver mutations. DNA methylation, histone modification, chromatin remodeling, and non-coding RNAs orchestrate aberrant transcriptional programs governing tumor initiation, progression, and cellular identity. Single-cell and multi-omic studies have revealed epigenetic heterogeneity, cellular plasticity, and microenvironmental interactions underlying therapeutic resistance. Epigenetic alterations provide valuable diagnostic and prognostic biomarkers. DNA methylation profiling is the gold standard for molecular classification, while epigenetic signatures and cerebrospinal fluid circulating tumor DNA support precision diagnosis and disease monitoring. This review integrates recent advances in MB epigenetics into a framework linking cellular plasticity and the tumor microenvironment to biomarker-driven precision therapies. Several comprehensive reviews have summarized the epigenetic landscape of medulloblastoma, focusing primarily on DNA methylation, histone modifications, chromatin remodeling, and subgroup-specific epigenetic alterations. While these studies have substantially advanced our understanding of epigenetic mechanisms, the rapid emergence of single-cell sequencing, spatial transcriptomics, multi-omic integration, and three-dimensional chromatin mapping has reshaped the current view of medulloblastoma biology. These technologies provide unprecedented resolution for dissecting intratumoral heterogeneity, developmental trajectories, and dynamic epigenetic regulation not fully addressed in earlier reviews. In this review, we integrate these recent advances into a unified framework connecting classical epigenetic mechanisms with emerging multidimensional epigenomic technologies. We discuss how these insights facilitate biomarker discovery, improve molecular classification, and accelerate precision epigenetic therapies, highlighting future directions for translational research.
- Open Access
- 11 August 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8) , e73030
Clinical Significance and Changes in Levels of Serum BDNF, mBDNF, AQP4, proBDNF, and GSK3β in Individuals Diagnosed With Bipolar Disorder: A Cross‐Sectional Study
Background and Aims: Bipolar disorder (BD) is a severe mood disorder with unclear pathogenesis and limited diagnostic biomarkers. This study aimed to evaluate serum levels of BDNF, mBDNF, AQP4, proBDNF, and GSK3β between BD patients and healthy controls, and to preliminarily explore their potential clinical significance. Methods: Thirty‐seven patients admitted to the Affiliated Hospital of Hangzhou Normal University with BD from November 2023 to September 2025 were selected as the study subjects, while 36 healthy blood donors from the Affiliated Hospital of Hangzhou Normal University, collected in April 2025, were selected as the control subjects to compare serum biomarkers levels of the two groups. Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value of serum biomarkers levels for bipolar disorder. Correlations between serum biomarkers were analyzed between the two groups. Results: The results revealed lower levels of BDNF and AQP4 and higher levels of mBDNF, proBDNF and GSK3β in the BD group compared to the healthy control group. Positive correlations were observed between serum BDNF and proBDNF, mBDNF and AQP4, as well as mBDNF and GSK3β levels in the BD group. Combining the serum biomarkers improved diagnostic accuracy compared to using individual serum biomarkers alone. Conclusion: In conclusion, patients with BD exhibit elevated serum levels of proBDNF and GSK3β compared to healthy controls, while the levels of BDNF, mBDNF, and AQP4 are significantly lower. These findings suggest that this serum biomarker panel may hold preliminary potential as a supportive indicator for BD. However, given the study's cross‐sectional design and lack of external validation, larger longitudinal cohorts are required to further evaluate its potential clinical significance.
- 11 August 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8) , e73030
Open AccessClinical Significance and Changes in Levels of Serum BDNF, mBDNF, AQP4, proBDNF, and GSK3β in Individuals Diagnosed With Bipolar Disorder: A Cross‐Sectional Study
Background and Aims: Bipolar disorder (BD) is a severe mood disorder with unclear pathogenesis and limited diagnostic biomarkers. This study aimed to evaluate serum levels of BDNF, mBDNF, AQP4, proBDNF, and GSK3β between BD patients and healthy controls, and to preliminarily explore their potential clinical significance. Methods: Thirty‐seven patients admitted to the Affiliated Hospital of Hangzhou Normal University with BD from November 2023 to September 2025 were selected as the study subjects, while 36 healthy blood donors from the Affiliated Hospital of Hangzhou Normal University, collected in April 2025, were selected as the control subjects to compare serum biomarkers levels of the two groups. Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value of serum biomarkers levels for bipolar disorder. Correlations between serum biomarkers were analyzed between the two groups. Results: The results revealed lower levels of BDNF and AQP4 and higher levels of mBDNF, proBDNF and GSK3β in the BD group compared to the healthy control group. Positive correlations were observed between serum BDNF and proBDNF, mBDNF and AQP4, as well as mBDNF and GSK3β levels in the BD group. Combining the serum biomarkers improved diagnostic accuracy compared to using individual serum biomarkers alone. Conclusion: In conclusion, patients with BD exhibit elevated serum levels of proBDNF and GSK3β compared to healthy controls, while the levels of BDNF, mBDNF, and AQP4 are significantly lower. These findings suggest that this serum biomarker panel may hold preliminary potential as a supportive indicator for BD. However, given the study's cross‐sectional design and lack of external validation, larger longitudinal cohorts are required to further evaluate its potential clinical significance.
- Open Access
- 25 June 2026
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 8
The application of CRISPR gene-editing technology in influenza prevention and control
Influenza A virus (IAV) and influenza B virus (IBV) remain major global public health threats because of their rapid antigenic evolution and efficient human-to-human transmission. In contrast, influenza C virus (ICV) and influenza D virus (IDV) generally exhibit narrower host ranges and milder pathogenicity, yet their potential for interspecies transmission and zoonotic spillover still warrants attention. Conventional prevention strategies, such as inactivated and live-attenuated vaccines, suffer from prolonged development timelines and diminished efficacy against rapidly evolving viral strains. However, antiviral drugs are increasingly limited by the rapid emergence of drug-resistant variants. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) gene-editing technology has emerged as a promising platform for influenza prevention and control owing to its programmability and precise targeting capability. In this paper, we summarize recent advances in CRISPR-based strategies for influenza prevention and control. The RNA-targeting CRISPR-associated protein 13 (Cas13) system can recognize conserved viral RNA sequences and suppress replication across influenza subtypes, whereas the DNA-targeting CRISPR-associated protein 9 (Cas9) system can edit host susceptibility genes and thereby reduce cellular permissiveness to infection. In addition, lipid nanoparticle (LNP)-based delivery systems have become important tools for improving the in vivo delivery and expression of CRISPR components by enhancing targeting efficiency and reducing immunogenicity. CRISPR-based diagnostics, such as Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK), further expand the clinical utility of this technology by enabling rapid and sensitive detection of influenza viruses. Despite these advances, substantial challenges remain, including delivery inefficiency, off-target activity, long-term safety concerns, and the risk of viral escape. With continued technological refinement and careful translational development, CRISPR may become a versatile tool for influenza prevention, diagnosis, and therapy.
- 25 June 2026
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 8
Open AccessThe application of CRISPR gene-editing technology in influenza prevention and control
Influenza A virus (IAV) and influenza B virus (IBV) remain major global public health threats because of their rapid antigenic evolution and efficient human-to-human transmission. In contrast, influenza C virus (ICV) and influenza D virus (IDV) generally exhibit narrower host ranges and milder pathogenicity, yet their potential for interspecies transmission and zoonotic spillover still warrants attention. Conventional prevention strategies, such as inactivated and live-attenuated vaccines, suffer from prolonged development timelines and diminished efficacy against rapidly evolving viral strains. However, antiviral drugs are increasingly limited by the rapid emergence of drug-resistant variants. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) gene-editing technology has emerged as a promising platform for influenza prevention and control owing to its programmability and precise targeting capability. In this paper, we summarize recent advances in CRISPR-based strategies for influenza prevention and control. The RNA-targeting CRISPR-associated protein 13 (Cas13) system can recognize conserved viral RNA sequences and suppress replication across influenza subtypes, whereas the DNA-targeting CRISPR-associated protein 9 (Cas9) system can edit host susceptibility genes and thereby reduce cellular permissiveness to infection. In addition, lipid nanoparticle (LNP)-based delivery systems have become important tools for improving the in vivo delivery and expression of CRISPR components by enhancing targeting efficiency and reducing immunogenicity. CRISPR-based diagnostics, such as Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK), further expand the clinical utility of this technology by enabling rapid and sensitive detection of influenza viruses. Despite these advances, substantial challenges remain, including delivery inefficiency, off-target activity, long-term safety concerns, and the risk of viral escape. With continued technological refinement and careful translational development, CRISPR may become a versatile tool for influenza prevention, diagnosis, and therapy.
- Open Access
- 9 October 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-9
Stem cell therapy for myocardial infarction and atherosclerosis: mechanisms, challenges, and future directions
Myocardial infarction (MI) and atherosclerosis (AS) are the deadliest category of diseases globally. Preliminary clinical and preclinical studies have shown that stem cell therapy can alleviate symptoms; however, it has not yet achieved full functional regeneration of myocardial or vascular tissues. Stem cell therapy has shown the ability to reverse pathological processes through tissue repair, angiogenesis, and immune modulation. The main challenges of clinical translation remain the low survival rate and uncontrolled differentiation after stem cell transplantation. This paper systematically describes the classification, characteristics, and mechanisms of action of stem cells, as well as the pathological features of MI and AS and the limitations of traditional therapy. It discusses the challenges and solutions for the clinical translation of stem cell therapy. Such advances are expected to promote the development of precise, intelligent, and systematic stem cell therapies for MI and AS. This is very useful for creating multidisciplinary innovation systems in the future.
- 9 October 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-9
Open AccessStem cell therapy for myocardial infarction and atherosclerosis: mechanisms, challenges, and future directions
Myocardial infarction (MI) and atherosclerosis (AS) are the deadliest category of diseases globally. Preliminary clinical and preclinical studies have shown that stem cell therapy can alleviate symptoms; however, it has not yet achieved full functional regeneration of myocardial or vascular tissues. Stem cell therapy has shown the ability to reverse pathological processes through tissue repair, angiogenesis, and immune modulation. The main challenges of clinical translation remain the low survival rate and uncontrolled differentiation after stem cell transplantation. This paper systematically describes the classification, characteristics, and mechanisms of action of stem cells, as well as the pathological features of MI and AS and the limitations of traditional therapy. It discusses the challenges and solutions for the clinical translation of stem cell therapy. Such advances are expected to promote the development of precise, intelligent, and systematic stem cell therapies for MI and AS. This is very useful for creating multidisciplinary innovation systems in the future.
- Open Access
- 5 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1570732
The advantages of TCM in the treatment of gynecologic malignancies
Gynecological malignancies are characterized by high morbidity and mortality rates. With the development of society, the status of women continues to improve, yet the social pressure they bear increases daily. The incidence rate of gynecological malignancies in the female population has always remained at a high level, and the age of onset has shown a trend of getting younger. Common gynecological malignancies include cervical cancer, ovarian cancer, and endometrial cancer. Alarmingly, over 70% of patients are diagnosed at an advanced stage. This disease is mainly treated through surgery and radiotherapy, but there is still a relatively high recurrence rate after treatment. In recent years, with the development of traditional Chinese medicine (TCM), the advantages of TCM in the treatment of gynecological malignancies have gradually emerged. The entry of TCM into the treatment of Gynecologic malignancies is a tumor treatment method that has received close attention from the international medical community in recent times. TCM can be used throughout the whole process of tumor treatment. Combining Western medicine at different stages of the tumor, or giving different Chinese medicines alone, can minimize the toxic side effects of Western medicine treatment, alleviate symptoms, prolong survival and improve the quality of survival. Therefore, combining traditional Chinese medicine to provide individualized treatment for patients may become a better approach to cancer treatment. This article reviews the status and important role of TCM in gynecological malignancies in the hope of exploring new treatment modalities to mitigate the impact of gynecological malignancies on women’s health.
- 5 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1570732
Open AccessThe advantages of TCM in the treatment of gynecologic malignancies
Gynecological malignancies are characterized by high morbidity and mortality rates. With the development of society, the status of women continues to improve, yet the social pressure they bear increases daily. The incidence rate of gynecological malignancies in the female population has always remained at a high level, and the age of onset has shown a trend of getting younger. Common gynecological malignancies include cervical cancer, ovarian cancer, and endometrial cancer. Alarmingly, over 70% of patients are diagnosed at an advanced stage. This disease is mainly treated through surgery and radiotherapy, but there is still a relatively high recurrence rate after treatment. In recent years, with the development of traditional Chinese medicine (TCM), the advantages of TCM in the treatment of gynecological malignancies have gradually emerged. The entry of TCM into the treatment of Gynecologic malignancies is a tumor treatment method that has received close attention from the international medical community in recent times. TCM can be used throughout the whole process of tumor treatment. Combining Western medicine at different stages of the tumor, or giving different Chinese medicines alone, can minimize the toxic side effects of Western medicine treatment, alleviate symptoms, prolong survival and improve the quality of survival. Therefore, combining traditional Chinese medicine to provide individualized treatment for patients may become a better approach to cancer treatment. This article reviews the status and important role of TCM in gynecological malignancies in the hope of exploring new treatment modalities to mitigate the impact of gynecological malignancies on women’s health.
- Open Access
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1495274
Advances in intestinal flora for the development, diagnosis and treatment of CRC
Colorectal cancer (CRC), being prevalent among digestive tract malignancies, exhibits substantial mortality and morbidity rates. The intestinal microbiota, predominantly located in the colorectum, is diverse and comprises both conditionally pathogenic bacteria that can promote CRC development and probiotics that can inhibit it to some extent. Intestinal flora is associated with colorectal cancer, affecting its onset and progression through metabolites, immune regulation, and damage to the intestinal mucosal barrier. The intestinal flora exhibits significant potential in the diagnosis and treatment of CRC. Certain bacterial species can serve as biomarkers for CRC, aiding in the detection of precancerous and early-stage lesions. For instance, alterations in the abundance of Fusobacterium nucleatum (Fn) and Enterotoxigenic Bacteroides fragilis (ETBF) may indicate an elevated risk of CRC. On the other hand, probiotics such as Bifidobacteria could modulate chemotherapy and immunotherapy, improving treatment outcomes and reducing side effects, making them an effective approach to prevent CRC etiology and act as an adjuvant therapy. This paper focuses on a review of the relationship between intestinal flora and CRC, sorting out its potential role in developing, diagnosing, and treating CRC. It will advance precise, intelligent, and individualised prevention and treatment for CRC.
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1495274
Open AccessAdvances in intestinal flora for the development, diagnosis and treatment of CRC
Colorectal cancer (CRC), being prevalent among digestive tract malignancies, exhibits substantial mortality and morbidity rates. The intestinal microbiota, predominantly located in the colorectum, is diverse and comprises both conditionally pathogenic bacteria that can promote CRC development and probiotics that can inhibit it to some extent. Intestinal flora is associated with colorectal cancer, affecting its onset and progression through metabolites, immune regulation, and damage to the intestinal mucosal barrier. The intestinal flora exhibits significant potential in the diagnosis and treatment of CRC. Certain bacterial species can serve as biomarkers for CRC, aiding in the detection of precancerous and early-stage lesions. For instance, alterations in the abundance of Fusobacterium nucleatum (Fn) and Enterotoxigenic Bacteroides fragilis (ETBF) may indicate an elevated risk of CRC. On the other hand, probiotics such as Bifidobacteria could modulate chemotherapy and immunotherapy, improving treatment outcomes and reducing side effects, making them an effective approach to prevent CRC etiology and act as an adjuvant therapy. This paper focuses on a review of the relationship between intestinal flora and CRC, sorting out its potential role in developing, diagnosing, and treating CRC. It will advance precise, intelligent, and individualised prevention and treatment for CRC.
- Open Access
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1560241
Immunotherapy of small cell lung cancer based on prognostic nutritional index
Platinum-based first-line chemotherapy for small lung cancers has been a mainstream therapy for the past several decades. However, its efficacy has been suboptimal, and the research is now focused on improving the treatment and prognosis of competitive nutrition and multidrug combination techniques. Small cell lung cancer (SCLC) is not only affected by smoking, age, sex and other external factors, but also the tumor micro-environment and the nutritional status of patients themselves are of great significance for the prevention and treatment of SCLC, a malignant tumor. According to past research, malnutrition is related to the intolerance to immunotherapy, decline in quality of life, psychological disturbances, and low survival rates and prognosis. Numerous studies have shown that a low Prognostic Nutritional Index (PNI) serves as an independent prognostic factor linked to reduced overall survival across various cancer types. Additionally, PNI has been associated with disease-free survival and progression-free survival in certain cancers, such as lung cancer (LC). Recent research has indicated that the PNI can serve as an independent predictor of both long-term outcomes and short-term complications in SCLC patients. However, a systematic consensus on this matter has yet to be established. This paper focuses on the role and influence of PNI in the immunotherapy of SCLC, and proposes the possibility of dietary therapy for SCLC patients under the guidance of PNI. Finally, the authors pointed out that PNI will become a new strategy for comprehensive immunotherapy of SCLC.
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1560241
Open AccessImmunotherapy of small cell lung cancer based on prognostic nutritional index
Platinum-based first-line chemotherapy for small lung cancers has been a mainstream therapy for the past several decades. However, its efficacy has been suboptimal, and the research is now focused on improving the treatment and prognosis of competitive nutrition and multidrug combination techniques. Small cell lung cancer (SCLC) is not only affected by smoking, age, sex and other external factors, but also the tumor micro-environment and the nutritional status of patients themselves are of great significance for the prevention and treatment of SCLC, a malignant tumor. According to past research, malnutrition is related to the intolerance to immunotherapy, decline in quality of life, psychological disturbances, and low survival rates and prognosis. Numerous studies have shown that a low Prognostic Nutritional Index (PNI) serves as an independent prognostic factor linked to reduced overall survival across various cancer types. Additionally, PNI has been associated with disease-free survival and progression-free survival in certain cancers, such as lung cancer (LC). Recent research has indicated that the PNI can serve as an independent predictor of both long-term outcomes and short-term complications in SCLC patients. However, a systematic consensus on this matter has yet to be established. This paper focuses on the role and influence of PNI in the immunotherapy of SCLC, and proposes the possibility of dietary therapy for SCLC patients under the guidance of PNI. Finally, the authors pointed out that PNI will become a new strategy for comprehensive immunotherapy of SCLC.
- Open Access
- 26 May 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (6) , 352
Recent Advancements in Understanding the Role and Mechanisms of Angiopoietin-like Proteins in Diabetic Retinopathy
Angiopoietin-like proteins (ANGPTLs) represent a family of secreted glycoproteins that are extensively expressed in vivo and are integral to various pathophysiological processes, including glucose and lipid metabolism, stem cell proliferation, local inflammation, vascular permeability, and angiogenesis. Particularly interesting is ANGPTL4, which has been identified as a significant factor in the development and progression of diabetic retinopathy (DR), thus becoming a central focus of DR research. ANGPTLs modulate metabolic pathways, enhance vascular permeability, and facilitate pathological angiogenesis, in addition to causing intraocular inflammation. As promising molecular targets, ANGPTLs not only serve as biomarkers for predicting the onset and progression of DR but also present therapeutic potential through antibody-based interventions. This paper discusses the pathogenesis of DR and the potential applications of ANGPTLs in early diagnosis and targeted therapy. It provides references for advancing precision diagnosis and personalized treatment strategies through more profound ANGPTLs research in the future.
- 26 May 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (6) , 352
Open AccessRecent Advancements in Understanding the Role and Mechanisms of Angiopoietin-like Proteins in Diabetic Retinopathy
Angiopoietin-like proteins (ANGPTLs) represent a family of secreted glycoproteins that are extensively expressed in vivo and are integral to various pathophysiological processes, including glucose and lipid metabolism, stem cell proliferation, local inflammation, vascular permeability, and angiogenesis. Particularly interesting is ANGPTL4, which has been identified as a significant factor in the development and progression of diabetic retinopathy (DR), thus becoming a central focus of DR research. ANGPTLs modulate metabolic pathways, enhance vascular permeability, and facilitate pathological angiogenesis, in addition to causing intraocular inflammation. As promising molecular targets, ANGPTLs not only serve as biomarkers for predicting the onset and progression of DR but also present therapeutic potential through antibody-based interventions. This paper discusses the pathogenesis of DR and the potential applications of ANGPTLs in early diagnosis and targeted therapy. It provides references for advancing precision diagnosis and personalized treatment strategies through more profound ANGPTLs research in the future.
- Open Access
- 15 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1582963
Recent advances in early diagnosis and treatment of T1D with miRNAs
Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β-cells and is one of the most common chronic diseases in adults and children. In recent years, the incidence of T1D has been increasing worldwide. Currently, the diagnosis of T1D relies on clinical manifestations and autoantibody detection, with a lack of early predictive biomarkers. MicroRNAs (miRNAs), as crucial post-transcriptional regulatory factors, which are involved in various biological processes, including cell division, proliferation, differentiation, development, and metabolism. Additionally, miRNAs participate in the regulation of inflammatory complications in T1D, and their aberrant expression is closely associated with the disease. The stability of miRNAs makes them potential candidates for early diagnostic biomarkers and therapeutic targets in T1D. This paper discusses the pathogenesis of T1D and the potential applications of miRNAs in early diagnosis and interventional therapy. It provides references for advancing precision diagnosis and personalized treatment strategies through more profound miRNA research in the future.
- 15 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1582963
Open AccessRecent advances in early diagnosis and treatment of T1D with miRNAs
Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β-cells and is one of the most common chronic diseases in adults and children. In recent years, the incidence of T1D has been increasing worldwide. Currently, the diagnosis of T1D relies on clinical manifestations and autoantibody detection, with a lack of early predictive biomarkers. MicroRNAs (miRNAs), as crucial post-transcriptional regulatory factors, which are involved in various biological processes, including cell division, proliferation, differentiation, development, and metabolism. Additionally, miRNAs participate in the regulation of inflammatory complications in T1D, and their aberrant expression is closely associated with the disease. The stability of miRNAs makes them potential candidates for early diagnostic biomarkers and therapeutic targets in T1D. This paper discusses the pathogenesis of T1D and the potential applications of miRNAs in early diagnosis and interventional therapy. It provides references for advancing precision diagnosis and personalized treatment strategies through more profound miRNA research in the future.